Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Return on Sales history runs 14 years deep, the most recent figure standing at 7.93% for Q1 2026.

• On a quarterly basis, Return on Sales rose 515.0% year-over-year to 7.93% in Q1 2026; TTM through Mar 2026 was 0.05%, a 1113.0% increase from a year earlier, with the FY2025 full-year figure at 0.09%, up 1567.0% from the prior year.
• Return on Sales fell to 7.93% in Q1 2026 per VRDN's latest filing, from 7.5% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q3 2025 and bottomed at 14.89% in Q2 2025.
• The 5-year median for Return on Sales is 7.65% (2023), against an average of 7.24%.
• Across the five-year window, Return on Sales plunged 735 bps in 2023 and surged 1063 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 4.34% in 2022, then slumped by 169 bps to 11.69% in 2023, then climbed by 6 bps to 10.98% in 2024, then surged by 32 bps to 7.5% in 2025, then declined by 6 bps to 7.93% in 2026.
• Per Business Quant, the three latest VRDN Return on Sales figures stand at 7.93% (Q1 2026), 7.5% (Q4 2025), and 0.0% (Q3 2025).